
A scanning electron micrograph of human sperm stuck together and immobilized by an antisperm antibody.
University of North Carolina Eshelman School of Pharmacy engineer ultra-potent sperm-binding monoclonal antibodies as option for affordable, non-hormonal female contraception
Scientists at the University of North Carolina at Chapel Hill are using the precision targeting of monoclonal antibodies for a new type of female contraception.
Monoclonal antibodies are known for their ability to fight off invading germs and are used to treat and prevent everything from cancer to COVID-19. Scientists are now looking at a new mission for antibodies: immobilizing sperm before it can reach an egg.
Carolina researchers have engineered ultra-potent antibodies that, during animal testing, effectively trapped and blocked more than 99.9% of human sperm. The promising study results published in Science Translational Medicine suggest contraceptives based on antibodies may offer women a non-hormonal option to prevent pregnancy.
“Many women avoid hormonal contraception because of real and perceived side effects,” said Samuel Lai, professor in the Division of Pharmacoengineering and Molecular Pharmaceutics at the UNC Eshelman School of Pharmacy.
These effects can include irregular bleeding, nausea, depression, weight gain and migraines. And for some women estrogen-based hormonal contraception can be harmful.
“There’s a major unmet need for alternative, non-hormonal contraceptives for women,” said Lai.
Antibodies as line of defense
Nearly half of all pregnancies in the United States are unintended, and Lai is among scientists across the country who are advancing the idea of using anti-sperm antibodies for contraception.
“We were inspired by infertility that occurs in some women who develop antibodies against their partner’s sperm,” said study first author Bhawana Shrestha, a doctoral student in the Department of Microbiology and Immunology at the UNC School of Medicine and graduate research assistant at the school of pharmacy.
The antibody they’re testing was isolated from an infertile woman and targets a unique surface antigen present on human sperm. When it’s added to sperm, the sperm quickly clump together.
“Using our highly multivalent IgG platform, we engineered antibodies that were more than 10 to 16 times more potent at agglutinating sperm and reducing sperm permeation through mucus than the best-known antibody,” she said.
Researchers explored the effect of antibodies in sheep, which have reproductive tracts similar to human females. At a high dose of 333 micrograms of antibody, both naturally occurring antibodies and the newly engineered antibodies, effectively stopped all human sperm motility, and at a low dose of 33.3 micrograms, the modified antibodies, but not the original ones, trapped 97% to 99% of sperm.
Next step: clinical trials
But monoclonal antibodies are known as expensive drugs, which puts their usefulness as an affordable contraceptive up in the air.
However, researchers believe that by increasing the potency, much lower doses of the multivalent antibodies may be needed for effective contraception.
“We think these second-generation molecules will provide not only greater potency but will translate to lower costs that make the approach cost-effective,” said Lai.
Mucommune, a startup spun out of the Lai Lab, has licensed the molecule for development of an antibody-based contraceptive. The company will focus on safety and manufacturing to prepare for human clinical trials that could start in 2023.
The team is working on incorporating the antibodies into an intravaginal ring that steadily releases the antibodies, or a dissolvable film placed in the vagina where it spreads antibodies before sex.
“By avoiding exogenous hormones and creating a women-controlled contraceptive method, we believe the antibodies developed here could meet the contraceptive needs for millions of women, help to reduce the number of unintended pregnancies and alleviate the health care costs of unintended pregnancies which some estimate to be in excess of $20 billion a year,” Lai said.
Original Article: Carolina scientists developing contraceptive that stops sperm in its tracks
More from: University of North Carolina at Chapel Hill | University of Texas Medical Branch | Boston University School of Medicine
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Non-hormonal female contraception
- Why Women Hate the Pillon December 6, 2023 at 8:05 am
She switched to a pill that was supposed to help manage the unwanted side effects, but her headaches became unbearable, often making her skull feel like it was about to crack open. Another pill with a ...
- This is the best time to stop using birth control if you're trying to get pregnanton December 5, 2023 at 2:42 am
IUDs. With hormonal IUDs, fertility usually returns shortly after removal and with copper IUDs, it often returns within the first menstrual cycle. Vaginal ring and contraceptive implant. Some women ...
- This is the best time to stop birth control if you're trying to get pregnanton December 4, 2023 at 6:16 pm
Whether you're taking the contraceptive pill or have an IUD or implant, this is when you should stop using it to maximise your chances of falling pregnant.
- Daré Bioscience launches Phase III hormone-free contraceptive trialon December 4, 2023 at 10:29 am
The hormone-free contraceptive trial is set to enrol around 250 patients as the company gears up to seek FDA approval.
- Daré Bioscience Announces Commencement of Phase 3 Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptiveon December 4, 2023 at 5:00 am
Approved Monthly, Self-Administered, Hormone-Free Contraceptive ProductSAN DIEGO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today ...
Go deeper with Google Headlines on:
Non-hormonal female contraception
[google_news title=”” keyword=”non-hormonal female contraception” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Sperm-binding monoclonal antibodies
- Antisperm Immunity and Infertilityon December 2, 2023 at 4:00 pm
It was shown, by immunobead binding, that immediate ... Lactate dehydrogenase; mAb: Monoclonal antibodies; NASP: Nuclear autoantigenic sperm protein; ZP: Zona pellucida. Features & Antifertility ...
- Quantifying GPIIb/IIIa Receptor Binding Using 2 Monoclonal Antibodieson November 27, 2023 at 4:00 pm
These antibodies may be used to monitor receptor number and occupancy during administration of a GPIIb/IIIa antagonist. Here, we describe the binding of 2 monoclonal antibodies to the platelet ...
- Monoclonal Antibodies in Biotechnologyon November 27, 2023 at 5:32 am
43, Issue. 2, p. 93. He, Jihong Shen, Jianzhong Suo, Xun Jiang, Haiyang and Hou, Xiaolin 2005. Development of a Monoclonal Antibody-based ELISA for Detection of Sulfamethazine and N4−acetyl ...
- Leading innovators in anti-interleukin monoclonal antibodies for the pharmaceutical industryon November 14, 2023 at 4:00 pm
Anti- interleukin (IL) humanized monoclonal antibodies are a type of biopharmaceutical drug that specifically target and bind to IL molecules – a type of cytokine – in the body, preventing their ...
- Antisperm Immunity and Infertilityon October 31, 2023 at 5:00 pm
The regional specificity of antibody binding limits the formation ... Lactate dehydrogenase; mAb: Monoclonal antibodies; NASP: Nuclear autoantigenic sperm protein; ZP: Zona pellucida.
Go deeper with Google Headlines on:
Sperm-binding monoclonal antibodies
[google_news title=”” keyword=”sperm-binding monoclonal antibodies” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]